Oncolytic virotherapy by HSV

Advances in Experimental Medicine and Biology

Volumn 1045, Issue , 2018, Pages 63-84

  Watanabe, Daisuke ^a   Goshima, Fumi ^b  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

G207; Herpes simplex virus; HF10; HSV; HSV1716; NV1020; Oncolytic virotherapy; OncoVEXGM CSF; T VEC; Talimogene laherparepvec

Indexed keywords

ACICLOVIR; CANERPATUREV; CAPSID PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FAMCICLOVIR; FLUOROURACIL; G 207; HSV 1716; METHOTREXATE; MITOMYCIN; NV 1020; ONCOLYTIC HERPES VIRUS; PROTEIN KINASE; RIBONUCLEOTIDE REDUCTASE; TALIMOGENE LAHERPAREPVEC; VIRUS GLYCOPROTEIN; ONCOLYTIC VIRUS;

ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLON CARCINOMA; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DNA REPLICATION; GENE EXPRESSION REGULATION; GENE STRUCTURE; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTOPENIA; MELANOMA; NATURAL KILLER CELL; NONHUMAN; NUCLEIC ACID METABOLISM; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS CAPSID; VIRUS GENOME; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; GENETICS; NEOPLASM; PHYSIOLOGY; PROCEDURES; SIMPLEXVIRUS; TRENDS;

ANIMALS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIMPLEXVIRUS;

EID: 85048601755     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-981-10-7230-7_4     Document Type: Chapter

References (84)

1. Advani SJ, Chung SM, Yan SY et al (1999) Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 59:2055–2058
2. Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780–2788
3. Bataille D, Epstein AL (1995) Herpes simplex virus type 1 replication and recombination. Biochimie 77:787–795
4. Boehmer PE, Nimonkar AV (2003) Herpes virus replication. IUBMB Life 55:3–22
5. Braidwood L, Graham SV, Graham A et al (2013) Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. Oncolytic Virother 2:57–74
6. Bringhurst RM, Schaffer PA (2006) Cellular stress rather than stage of the cell cycle enhances the replication and plating efficiencies of herpes simplex virus type 1 ICP0-viruses. J Virol 80:4528–4537
7. Cozzi PJ, Malhotra S, Mcauliffe P et al (2001) Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 15:1306–1308
8. DePace NG (1912) Sulla Scomparsa di un enorme cancro begetante del callo dell’utero senza cura chirurgica [Italian]. Ginecol 9:82
9. Dock G (1904) Influence of complicating diseases upon leukemia. Am J Med Sci 127:563–592
10. Dossett LA, Kudchadkar RR, Zager JS (2015) BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf 14:559–570
11. Ebright MI, Zager JS, Malhotra S et al (2002) Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg 124:123–129
12. Esaki S, Goshima F, Kimura H et al (2013) Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. Int J Cancer 132:1592–1601
13. Fu X, Zhang X (2002) Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 62:2306–2312
14. Fujimoto Y, Mizuno T, al SS (2006) Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 126:1115–1117
15. Gambini E, Reisoli E, Appolloni I et al (2012) Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther 20:994–1001
16. Geevarghese SK, Geller DA, De Haan HA et al (2010) Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 21:1119–1128
17. Harrington KJ, Hingorani M, Tanay MA et al (2010) Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 16:4005–4015
18. Harrow S, Papanastassiou V, Harland J et al (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11:1648–1658
19. Hill A, Jugovic P, York I et al (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411–415
20. GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12:6737–6747
21. Huebner RJ, Rowe WP, Schatten WE et al (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9:1211–1218
22. Hummel JL, Safroneeva E, Mossman KL (2005) The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 12:1101–1110
23. Jackson C, Browell D, Gautrey H et al (2013) Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance. Int J Cell Biol 2013:973584
24. Jones C, Inman M, Peng W et al (2005) The herpes simplex virus type 1 locus that encodes the latency-associated transcript enhances the frequency of encephalitis in male BALB/c mice. J Virol 79:14465–14469
25. Kanai R, Zaupa C, Sgubin D et al (2012) Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol 86:4420–4431
26. Kaufman HL, Kim DW, DeRaffele G et al (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:718–730
27. Kemeny N, Brown K, Covey A et al (2006) Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17:1214–1224
28. Kimata H, Takakuwa H, Goshima F et al (2003) Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepato-Gastroenterology 50:961–966
29. Kimata H, Imai T, Kikumori T et al (2006) Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 13:1078–1084
30. Kohno S, Luo C, Goshima F et al (2005) Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer. Urology 66:1116–1121
31. Kohno SI, Luo C, Nawa A et al (2007) Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther 14:918–926
32. Kong Y, Yang T, Geller AI (1999) An efficient in vivo recombination cloning procedure for modifying and combining HSV-1 cosmids. J Virol Methods 80:129–136
33. Koshizuka T, Kawaguchi Y, Nishiyama Y (2005) Herpes simplex virus type 2 mem-brane protein UL56 associates with the kinesin motor protein KIF1A. J Gen Virol 86:527–533
34. Lilley CE, Carson CT, Muotri AR et al (2005) DNA repair proteins affect the lifecycle of herpes simplex virus 1. Proc Natl Acad Sci U S A 102:5844–5849
35. Liu BL, Robinson M, Han ZQ et al (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10:292–303
36. MacKie RM, Stewart B, Brown SM (2001) Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357:525–526
37. Markert JM, Liechty PG, Wang W et al (2009) Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17:199–207
38. Markert JM, Razdan SN, Kuo HC et al (2014) A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 22:1048–1055
39. Martuza RL, Malick A, Markert JM et al (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854–885
40. Marconi P, Argnani R, Berto E et al (2008) HSV as a vector in vaccine development and gene therapy. Hum Vaccin 4:91–105
41. McGeoch DJ, Dalrymple MA, Davison AJ et al (1988) The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 69:1531–1574
42. Menotti L, Cerretani A, Hengel H et al (2008) Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 82(20):10153–10161
43. Mineta T, Rabkin SD, Yazaki T et al (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938–943
44. Mori I, Nishiyama Y (2005) Herpes simplex virus and varicella-zoster virus: why do these human alphaherpesviruses behave so differently from one another? Rev Med Virol 15:393–406
45. Mori I, Nishiyama Y (2006) Accessory genes define the relationship between the herpes simplex virus and its host. Microbes Infect 8:2556–2562
46. Mullerad M, Bochner BH, Adusumilli PS et al (2005) Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol 174:741–746
47. Nakamura H, Mullen JT, Chandrasekhar S et al (2001) Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 61:5447–5452
48. Nakao A, Kimata H, et al (2004) Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 15:988–989
49. Nakashima H, Chiocca EA (2014) Modification of HSV-1 to an oncolytic virus. Methods Mol Biol 1144:117–127
50. Nanni P, Gatta V, Menotti L et al (2013) Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog 9:e1003155
51. Nawa A, Luo C, Zhang L et al (2008) Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr Gene Ther 8:208–221
52. Nishiyama Y (1996) Herpesvirus genes: molecular basis of viral replication and pathogenicity. Nagoya J Med Sci 59:107–119
53. Nishiyama Y (2004) Herpes simplex virus gene products: the accessories reflect her lifestyle well. Rev Med Virol 14:33–46
54. Nishiyama Y, Kimura H, Daikoku T (1991) Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2. J Virol 65:4520–4524
55. Pérez-Herrero E, Fernández-Medarde A (2015) Advanced targeted therapies in cancer: drug nano-carriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79
56. Pourchet A, Fuhrmann SR, Pilones KA et al (2016) CD8(+) T-cell immune evasion enables oncolytic virus immunotherapy. EBioMedicine 5:59–67
57. Puzanov I, Milhem MM, Minor D et al (2016) Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 34:2619–2626
58. Salameh S, Sheth U, Shukla D (2012) Early events in herpes simplex virus lifecycle with implications for an infection of lifetime. Open Virol J 6:1–6
59. Sengupta S, Thaci B, Crawford AC et al (2014) Interleukin-13 receptor alpha 2-targeted glioblas-toma immunotherapy. Biomed Res Int 2014:952128
60. Senzer NN, Kaufman HL, Amatruda T et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763–5771
61. Sobol PT, Mossman KL (2006) ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells. J Virol 80:218–225
62. Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60
63. Spear MA, Sun F, Eling DJ et al (2000) Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther 7:1051–1059
64. Stanziale SF, Petrowsky H, Adusumilli PS et al (2004) Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res 10:3225–3232
65. Stavropoulos TA, Strathdee CA (1998) An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 72:7137–7143
66. Stiles BM, Adusumilli PS, Bhargava A et al (2006a) Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. Cancer Gene Ther 13:53–64
67. Stiles BM, Adusumilli PS, Stanziale SF et al (2006b) Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. Int J Oncol 28:1429–1439
68. Sundaresan P, Hunter WD, Martuza RL et al (2000) Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 74:3832–3841
69. Sze DY, Iagaru AH, Gambhir SS et al (2012) Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography. Hum Gene Ther 23:91–97
70. Sze DY, Reid TR, Rose SC (2013) Oncolytic virotherapy. J Vasc Interv Radiol 24:1115–1122
71. Takakuwa H, Goshima F, Nozawa N et al (2003) Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immuno-competent mice. Arch Virol 148:813–825
72. Tanaka M, Kagawa H, Yamanashi Y et al (2003) Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J Virol 77:1382–1391
73. Tang T, Eldabaje R, Yang L (2016) Current status of biological therapies for the treatment of metastatic melanoma. Anticancer Res 36:3229–3241
74. Taylor TJ, Brockman MA, McNamee EE et al (2002) Herpes simplex virus. Front Biosci 7:d752–d764
75. Teshigahara O, Goshima F, Takao K et al (2004) Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol 85:42–47
76. Todo T (2008) Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 200813:2060–2064
77. Todo T, Feigenbaum F, Rabkin SD et al (2000) Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2:588–595
78. Toyoizumi T, Mick R, Abbas AE et al (1999) Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 10:3013–3029
79. Ushijima Y, Luo C, Goshima F et al (2007) Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes Infect 9:142–149
80. Watanabe D, Goshima F, Mori I et al (2008) Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci 50:185–196
81. Witt MN, Braun GS, Ihrler S et al (2009) Occurrence of HSV-1-induced pneumonitis in patients under standard immunosuppressive therapy for rheumatic, vasculitic, and connective tissue disease. BMC Pulm Med 18:22
82. Zabierowski SE, Deluca NA (2008) Stabilized binding of TBP to the TATA box of herpes simplex virus type 1 early (tk) and late (gC) promoters by TFIIA and ICP4. J Virol 82:3546–3554
83. Zhou G, Roizman B (2006) Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A 103:5508–5513
84. Zhou G, Ye GJ, al DW (2002) Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A 99:15124–15129